RESUMO
PURPOSE: To study the incidence of suture-related complications following penetrating keratoplasty (PK) and their effect on the success of corneal grafting. METHODS: The records of 332 patients receiving 361 grafts in 1993 and 1994 were reviewed, and suture-related complications were recorded. These complications were divided into five groups: suture erosions, infiltrates at the suture sites, infectious keratitis, loose sutures with imminent wound dehiscence, and wound dehiscence after suture removal. RESULTS: Occurrence rates were suture erosions, 10.8%; infiltrates, 9.4%; infectious keratitis related to sutures, 3.3%; loose sutures with imminent wound separation in need of surgical repair, 8.3%; and wound dehiscence following suture removal, 2.4%. CONCLUSIONS: Suture-related complications frequently occur after PK. Infectious keratitis and wound separations needing surgical repair may lead to loss of best-corrected visual acuity due to scarring, induced allograft reactions, and/or increased astigmatism. Recommendations for post-PK suture management are proposed.
Assuntos
Ceratoplastia Penetrante , Complicações Pós-Operatórias , Técnicas de Sutura/efeitos adversos , Extração de Catarata , Doenças da Córnea/cirurgia , Infecções Oculares Bacterianas/etiologia , Feminino , Humanos , Incidência , Ceratite/microbiologia , Implante de Lente Intraocular , Masculino , Reoperação , Estudos Retrospectivos , Deiscência da Ferida Operatória/etiologia , Fatores de Tempo , Acuidade VisualAssuntos
Nitroquinolinas/uso terapêutico , Oxamniquine/uso terapêutico , Praziquantel/uso terapêutico , Esquistossomose mansoni/tratamento farmacológico , Ensaios Clínicos como Assunto , Método Duplo-Cego , Feminino , Humanos , Masculino , Oxamniquine/efeitos adversos , Praziquantel/efeitos adversos , Schistosoma mansoni/efeitos dos fármacosRESUMO
In an attempt to reproduce experimentally as close a possible the conditions found in endemic areas of mansonian schistosomiasis, a controlled trial in mice submitted to weakly infections with cercariae of S. mansoni was performed. One group (I) was not treated, the other (II) was treated with a single oral doses (100 mg/kg) of oxamniquine at the 13th week. After treatment infections were maintained bi-weekly. Mortality was significantly higher in group I (p less than 0.0001). A comparative morphological and immunoenzymatic study of the liver in the two groups was also carried out, showing a tendency to smaller granulomas and to more efficient antigen restriction in the treated group.
Assuntos
Nitroquinolinas/uso terapêutico , Oxamniquine/uso terapêutico , Esquistossomose mansoni/tratamento farmacológico , Administração Oral , Animais , Antígenos de Helmintos/análise , Ductos Biliares Intra-Hepáticos/patologia , Feminino , Granuloma/patologia , Técnicas Imunoenzimáticas , Fígado/patologia , Hepatopatias/patologia , Masculino , Camundongos , Oxamniquine/administração & dosagem , Estudos Prospectivos , Distribuição Aleatória , Schistosoma mansoni/imunologia , Esquistossomose mansoni/imunologia , Esquistossomose mansoni/parasitologia , Esquistossomose mansoni/patologiaRESUMO
Camundongos imunizados com tripomastigotas de cultura da cepa G, mortos pelo calor ou mertiolato, mostraram-se resistentes a infeccao por tripomastigotas da cepa CL de T. cruzi provenientes do inseto vetor. Em 90% dos camundongos imunizados nao foi detectada parasitemia patente ao exame microscopico enquanto todos os animais-controle desenvolveram alta parasitemia.Tripsinizacao seguida de aquecimento, ou fixacao com para-formaldeido, aparentemente reduziram a imunogenicidade de tripomastigotas da cepa G, visto que camundongos imunizados com tripomastigotas tratados por qualquer destes metodos nao foram protegidos contra infeccao por T. cruzi.A analise de proteinas de superficie de tripomastigotas da cepa G, inativados por diferentes metodos, marcados com 131I, sugere que esses componentes de superficie estao envolvidos na inducao da imunidade protetora contra T. cruzi
Assuntos
Animais , Camundongos , Doença de Chagas , Trypanosoma cruzi , Imunidade CelularRESUMO
UNLABELLED: 40 patients with the hepatosplenic form of schistosomiasis mansoni were selected for this study. Among 29 patients submitted to oral endoscopy there were 28 in whom oesophageal varices were demonstrated and 20 out of 21 patients who presented gastrointestinal haemorrhage had been operated on. All patients received a single oral dose of 40 mg/kg b.w. of 2-cyclohexylcarbonyl-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one (praziquantel, EMBAY 8440, Biltricide). Unwanted side effects were recorded when spontaneously reported. These were rather frequent but generally mild and disappeared within hours without additional medication. Comprehensive laboratory tests as well as ECG and EEG dit not show any significant changes. 27 patients were parasitologically followed up for 3-6 months; 26 of them were egg-negative. In the 18 patients who could be followed up for more than 6 months, the cure rate was 94.4%. CONCLUSION: praziquantel can be safely given also to patients with hepatosplenic complications.